Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice.

Li Y, Tinoco R, Elmén L, Segota I, Xian Y, Fujita Y, Sahu A, Zarecki R, Marie K, Feng Y, Khateb A, Frederick DT, Ashkenazi SK, Kim H, Perez EG, Day CP, Segura Muñoz RS, Schmaltz R, Yooseph S, Tam MA, Zhang T, Avitan-Hersh E, Tzur L, Roizman S, Boyango I, Bar-Sela G, Orian A, Kaufman RJ, Bosenberg M, Goding CR, Baaten B, Levesque MP, Dummer R, Brown K, Merlino G, Ruppin E, Flaherty K, Ramer-Tait A, Long T, Peterson SN, Bradley LM, Ronai ZA.

Nat Commun. 2019 Apr 2;10(1):1492. doi: 10.1038/s41467-019-09525-y.

2.

Something Old, Something New: The Tumor Microenvironment Comes of Age.

Marie KL, Merlino G.

Cancer Discov. 2019 Jan;9(1):19-21. doi: 10.1158/2159-8290.CD-18-1320.

3.

Partial Rescue of Ocular Pigment Cells and Structure by Inducible Ectopic Expression of Mitf-M in MITF-Deficient Mice.

Michael HT, Graff-Cherry C, Chin S, Rauck C, Habtemichael AD, Bunda P, Smith T, Campos MM, Bharti K, Arnheiter H, Merlino G, Day CP.

Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):6067-6073. doi: 10.1167/iovs.18-25186.

4.

A direct link between MITF, innate immunity, and hair graying.

Harris ML, Fufa TD, Palmer JW, Joshi SS, Larson DM, Incao A, Gildea DE, Trivedi NS, Lee AN, Day CP, Michael HT, Hornyak TJ, Merlino G; NISC Comparative Sequencing Program, Pavan WJ.

PLoS Biol. 2018 May 3;16(5):e2003648. doi: 10.1371/journal.pbio.2003648. eCollection 2018 May.

5.

PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Yu Y, Dai M, Lu A, Yu E, Merlino G.

Oncogene. 2018 Apr;37(17):2225-2236. doi: 10.1038/s41388-017-0061-7. Epub 2018 Feb 2.

6.

Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.

Hernandez B, Adissu HA, Wei BR, Michael HT, Merlino G, Simpson RM.

Int J Mol Sci. 2018 Jan 30;19(2). pii: E394. doi: 10.3390/ijms19020394. Review.

7.

Pigmented Epithelioid Melanocytoma (PEM)/Animal Type Melanoma (ATM): Quest for an Origin. Report of One Unusual Case Indicating Follicular Origin and Another Arising in an Intradermal Nevus.

Tarasen A, Carlson JA, Leonard MK, Merlino G, Kaetzel D, Slominski AT.

Int J Mol Sci. 2017 Aug 15;18(8). pii: E1769. doi: 10.3390/ijms18081769.

8.

A Topical Solution to the Sunless Tanning Problem.

Michael HT, Merlino G.

Trends Mol Med. 2017 Sep;23(9):771-773. doi: 10.1016/j.molmed.2017.07.010. Epub 2017 Aug 5.

9.

Identification of essential genes for cancer immunotherapy.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP.

Nature. 2017 Aug 31;548(7669):537-542. doi: 10.1038/nature23477. Epub 2017 Aug 7.

10.

Genetically engineered mouse models of melanoma.

Pérez-Guijarro E, Day CP, Merlino G, Zaidi MR.

Cancer. 2017 Jun 1;123(S11):2089-2103. doi: 10.1002/cncr.30684. Review.

11.

Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevance.

Day CP, Marchalik R, Merlino G, Michael H.

Lab Invest. 2017 Jun;97(6):698-705. doi: 10.1038/labinvest.2016.155. Epub 2017 Jan 16. Review.

12.

Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.

Mishra PJ, Mishra PJ, Merlino G.

PLoS One. 2016 Nov 15;11(11):e0165102. doi: 10.1371/journal.pone.0165102. eCollection 2016.

13.

Concepts in Cancer Modeling: A Brief History.

Thomas RM, Van Dyke T, Merlino G, Day CP.

Cancer Res. 2016 Oct 15;76(20):5921-5925. Epub 2016 Sep 30. Review.

14.

Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.

Wei BR, Michael HT, Halsey CH, Peer CJ, Adhikari A, Dwyer JE, Hoover SB, El Meskini R, Kozlov S, Weaver Ohler Z, Figg WD, Merlino G, Simpson RM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):643-655. doi: 10.1111/pcmr.12512. Epub 2016 Sep 22.

15.

MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.

Cataisson C, Michalowski AM, Shibuya K, Ryscavage A, Klosterman M, Wright L, Dubois W, Liu F, Zhuang A, Rodrigues KB, Hoover S, Dwyer J, Simpson MR, Merlino G, Yuspa SH.

Sci Signal. 2016 Jun 21;9(433):ra62. doi: 10.1126/scisignal.aaf5106.

16.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

17.

Preclinical mouse cancer models: a maze of opportunities and challenges.

Day CP, Merlino G, Van Dyke T.

Cell. 2015 Sep 24;163(1):39-53. doi: 10.1016/j.cell.2015.08.068. Review.

18.

Molecular profile of clonal strains of human skeletal stem/progenitor cells with different potencies.

Sworder BJ, Yoshizawa S, Mishra PJ, Cherman N, Kuznetsov SA, Merlino G, Balakumaran A, Robey PG.

Stem Cell Res. 2015 May;14(3):297-306. doi: 10.1016/j.scr.2015.02.005. Epub 2015 Feb 25.

19.

Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.

Shakhova O, Cheng P, Mishra PJ, Zingg D, Schaefer SM, Debbache J, Häusel J, Matter C, Guo T, Davis S, Meltzer P, Mihic-Probst D, Moch H, Wegner M, Merlino G, Levesque MP, Dummer R, Santoro R, Cinelli P, Sommer L.

PLoS Genet. 2015 Jan 28;11(1):e1004877. doi: 10.1371/journal.pgen.1004877. eCollection 2015 Jan.

20.

mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M.

Cancer Cell. 2015 Jan 12;27(1):41-56. doi: 10.1016/j.ccell.2014.11.014.

Supplemental Content

Loading ...
Support Center